S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot

Lipocine (LPCN) Competitors

$3.83
+0.02 (+0.52%)
(As of 03/1/2024 ET)

LPCN vs. MTEM, QLI, TLPH, ITRM, APRE, ALRN, KALA, SNSE, TXMD, and GLTO

Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Molecular Templates (MTEM), Qilian International Holding Group (QLI), Talphera (TLPH), Iterum Therapeutics (ITRM), Aprea Therapeutics (APRE), Aileron Therapeutics (ALRN), KALA BIO (KALA), Sensei Biotherapeutics (SNSE), TherapeuticsMD (TXMD), and Galecto (GLTO). These companies are all part of the "pharmaceutical preparations" industry.

Lipocine vs.

Lipocine (NASDAQ:LPCN) and Molecular Templates (NASDAQ:MTEM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations.

Lipocine received 1 more outperform votes than Molecular Templates when rated by MarketBeat users. Likewise, 71.46% of users gave Lipocine an outperform vote while only 67.32% of users gave Molecular Templates an outperform vote.

CompanyUnderperformOutperform
LipocineOutperform Votes
343
71.46%
Underperform Votes
137
28.54%
Molecular TemplatesOutperform Votes
342
67.32%
Underperform Votes
166
32.68%

9.0% of Lipocine shares are held by institutional investors. 5.0% of Lipocine shares are held by insiders. Comparatively, 18.7% of Molecular Templates shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Lipocine had 1 more articles in the media than Molecular Templates. MarketBeat recorded 2 mentions for Lipocine and 1 mentions for Molecular Templates. Molecular Templates' average media sentiment score of 1.87 beat Lipocine's score of 0.93 indicating that Molecular Templates is being referred to more favorably in the news media.

Company Overall Sentiment
Lipocine Positive
Molecular Templates Very Positive

Lipocine has higher earnings, but lower revenue than Molecular Templates. Lipocine is trading at a lower price-to-earnings ratio than Molecular Templates, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipocine$500K40.75-$10.76M-$3.14-1.22
Molecular Templates$19.75M1.00-$92.72M-$6.67-0.55

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lipocine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Molecular Templates
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Lipocine has a net margin of 0.00% compared to Molecular Templates' net margin of -49.57%. Molecular Templates' return on equity of 0.00% beat Lipocine's return on equity.

Company Net Margins Return on Equity Return on Assets
LipocineN/A -54.96% -51.42%
Molecular Templates -49.57%N/A -43.85%

Lipocine has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Molecular Templates has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Summary

Lipocine beats Molecular Templates on 8 of the 15 factors compared between the two stocks.


Get Lipocine News Delivered to You Automatically

Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LPCN vs. The Competition

MetricLipocinePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$20.38M$7.09B$5.20B$7.62B
Dividend YieldN/A2.84%2.82%3.87%
P/E Ratio-1.2211.27206.0316.04
Price / Sales40.75242.433,031.0680.30
Price / CashN/A18.9799.1555.35
Price / Book0.564.674.524.54
Net Income-$10.76M$155.80M$114.88M$211.55M
7 Day Performance0.52%7.79%5.69%3.36%
1 Month Performance-2.79%15.86%11.23%6.68%
1 Year Performance-47.73%8.96%14.04%8.85%

Lipocine Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MTEM
Molecular Templates
1.8859 of 5 stars
$3.95
+5.6%
N/A-46.6%$21.21M$19.75M-0.59111Positive News
High Trading Volume
QLI
Qilian International Holding Group
0 of 5 stars
$0.60
+1.7%
N/A-66.0%$21.45M$46.47M0.00345Short Interest ↓
News Coverage
Gap Down
TLPH
Talphera
2.2674 of 5 stars
$1.23
-1.6%
$6.00
+387.8%
N/A$20.85M$1.77M-0.5519Upcoming Earnings
Short Interest ↓
News Coverage
Gap Down
ITRM
Iterum Therapeutics
2.313 of 5 stars
$1.47
-0.7%
$6.00
+308.2%
+13.0%$19.76MN/A-0.6014Gap Down
APRE
Aprea Therapeutics
3.5991 of 5 stars
$6.13
+5.1%
$14.50
+136.5%
+53.6%$22.93MN/A-1.549Short Interest ↓
News Coverage
Positive News
ALRN
Aileron Therapeutics
3.3354 of 5 stars
$4.72
+0.6%
$9.00
+90.7%
+235.6%$23.08MN/A0.006Short Interest ↓
News Coverage
KALA
KALA BIO
4.6819 of 5 stars
$7.17
+1.1%
$22.00
+206.8%
-27.9%$19.29M$3.89M-0.3234Short Interest ↓
Gap Up
SNSE
Sensei Biotherapeutics
4.8172 of 5 stars
$0.76
flat
$4.00
+426.3%
-50.0%$19MN/A-0.5826News Coverage
Positive News
Gap Up
TXMD
TherapeuticsMD
0.8386 of 5 stars
$2.27
+0.4%
N/A-49.2%$24.02M$69.96M0.001Analyst Report
News Coverage
GLTO
Galecto
3.2074 of 5 stars
$0.68
-2.8%
$7.60
+1,011.4%
-61.1%$18.54MN/A-0.3945Short Interest ↓
News Coverage
Gap Up

Related Companies and Tools

This page (NASDAQ:LPCN) was last updated on 3/3/2024 by MarketBeat.com Staff